Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Clinical Endocrinology and Metabolism|December 14, 2020
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly SomapacitanRasmus Juul Kildemoes, Michael Højby Rasmussen, Henrik Agersø, et al.
Clinical Pharmacokinetics|April 17, 2021
Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin<sup>®</sup> in Children and AdultsTheodoros Papathanasiou, Henrik Agersø, Birgitte Bentz Damholt, et al.
Clinical Pharmacokinetics|May 10, 2021
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology TrialsRune V Overgaard, Andrea Navarria, Steen H Ingwersen, et al.
Clinical Pharmacokinetics|July 5, 2024
Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover TrialSarah Louise Dombernowsky, Birgitte Bentz Damholt, Michael Højby Rasmussen, et al.
European Journal of Endocrinology|May 6, 2022
Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiencyRasmus Juul Kildemoes, Christian Hollensen, Beverly M K Biller, et al.
Journal of the Endocrine Society|June 29, 2026
Model-based somapacitan dosing and IGF-I response in children born SGA or with ISS, Noonan or Turner syndromesJulie Desrochers, Philippe Backeljauw, Michael Højby, et al.
European Journal of Endocrinology|January 18, 2023
Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 studyAnders Juul, Philippe Backeljauw, Michael Højby, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2024
Somapacitan in Children Born SGA: 52-Week Efficacy, Safety, and IGF-I Response Results From the Phase 2 REAL5 StudyAnders Juul, Philippe Backeljauw, Michael Højby, et al.
The Journal of Clinical Endocrinology and Metabolism|September 5, 2022
Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 TrialBradley S Miller, Joanne C Blair, Michael Højby Rasmussen, et al.
The AAPS Journal|September 4, 2024
A Risk-Based Assessment for Determining the Pharmacokinetic Comparability Requirements of Biologic-Device Combination Products Administered by Subcutaneous InjectionMark Klitgaard Nøhr, Shaik Rizwan Waheed, Rasmus Juul Kildemoes, et al.
Pageof 1